$CVM
CEL SCI CORP Stock $cvm

$cvm Overview Financials Valuation SEC Filings Company Website

2025 Q1 Form 10-K Financial Statement

#000165495425000288 Filed on January 13, 2025

Income Statement

Concept	2025 Q1	2024 Q3	2024
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development			$18.16M
YoY Change			-19.18%
% of Gross Profit
Depreciation & Amortization			$2.135M
YoY Change			0.99%
% of Gross Profit
Operating Expenses			$26.35M
YoY Change			-16.28%
Operating Profit			-$26.35M
YoY Change			-16.28%
Interest Expense			$745.7K
YoY Change			10.4%
% of Operating Profit
Other Income/Expense, Net			$177.7K
YoY Change			-515.02%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings			-$27.58M
YoY Change			-14.33%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share			-$0.51
COMMON SHARES
Basic Shares Outstanding	74.11M shares	61.49M shares
Diluted Shares Outstanding			54.04M shares

Balance Sheet

Concept	2025 Q1	2024 Q3	2024
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents		$4.738M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory		$1.020M
Prepaid Expenses		$294.1K
Receivables
Other Receivables
Total Short-Term Assets		$6.056M
YoY Change		-12.47%
LONG-TERM ASSETS
Property, Plant & Equipment		$8.130M
YoY Change		-20.2%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets		$20.94M
YoY Change		-11.32%
TOTAL ASSETS
Total Short-Term Assets		$6.056M
Total Long-Term Assets		$20.94M
Total Assets		$26.99M
YoY Change		-11.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$1.448M
YoY Change		-27.93%
Accrued Expenses		$566.0K
YoY Change		-46.07%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities		$4.616M
YoY Change		-17.37%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities		$125.0K
YoY Change		0.0%
Total Long-Term Liabilities		$125.0K
YoY Change		0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities		$4.616M
Total Long-Term Liabilities		$125.0K
Total Liabilities		$14.12M
YoY Change		-18.42%
SHAREHOLDERS EQUITY
Retained Earnings		-$514.0M
YoY Change		5.53%
Common Stock		$637.9K
YoY Change		34.51%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		$12.87M
YoY Change
Total Liabilities & Shareholders Equity		$26.99M
YoY Change		-11.58%

Cashflow Statement

Concept	2025 Q1	2024 Q3	2024
OPERATING ACTIVITIES
Net Income			-$27.58M
YoY Change			-14.33%
Depreciation, Depletion And Amortization			$2.135M
YoY Change			0.99%
Cash From Operating Activities			-$18.81M
YoY Change			-17.67%
INVESTING ACTIVITIES
Capital Expenditures			$94.88K
YoY Change			-73.78%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities			-$108.1K
YoY Change			-70.97%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$23.58M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities			$19.51M
YoY Change			315.64%
NET CHANGE
Cash From Operating Activities			-$18.81M
Cash From Investing Activities			-$108.1K
Cash From Financing Activities			$19.51M
Net Change In Cash			$592.4K
YoY Change			-103.2%
FREE CASH FLOW
Cash From Operating Activities			-$18.81M
Capital Expenditures			$94.88K
Free Cash Flow			-$18.91M
YoY Change			-18.54%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	4615779	usd
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0000725363
CY2024	dei	Amendment Flag AmendmentFlag	false
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2024	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	63787104	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47422304	shares
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	200000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	7957925	usd
CY2023Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	9949565	usd
CY2023Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1425979	usd
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	cvm	Employee Contributions To Defined Contribution Plans EmployeeContributionsToDefinedContributionPlans	10000	usd
CY2024	dei	Document Type DocumentType	10-K
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
CY2024	dei	Document Transition Report DocumentTransitionReport	false
CY2024	dei	Entity File Number EntityFileNumber	1-11889
CY2024	dei	Entity Registrant Name EntityRegistrantName	CEL-SCI CORPORATION
CY2024	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	CO
CY2024	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-0916344
CY2024	dei	Entity Address Address Line1 EntityAddressAddressLine1	8229 Boone Blvd.
CY2024	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 802
CY2024	dei	Entity Address City Or Town EntityAddressCityOrTown	Vienna
CY2024	dei	Entity Address State Or Province EntityAddressStateOrProvince	VA
CY2024	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	22182
CY2024	dei	City Area Code CityAreaCode	703
CY2024	dei	Local Phone Number LocalPhoneNumber	506-9460
CY2024	dei	Security12b Title Security12bTitle	Common Stock
CY2024	dei	Trading Symbol TradingSymbol	CVM
CY2024	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	true
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2024Q1	dei	Entity Public Float EntityPublicFloat	100002189	usd
CY2025Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	74107041	shares
CY2024	dei	Auditor Firm AuditorFirmId	243
CY2024	dei	Auditor Name AuditorName	BDO USA, P.C.
CY2024	dei	Auditor Location AuditorLocation	Potomac, Maryland
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4738173	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4145735	usd
CY2024Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	294097	usd
CY2023Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	520368	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	1019908	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	2248072	usd
CY2024Q3	us-gaap	Deposits Assets Current DepositsAssetsCurrent	3500	usd
CY2023Q3	us-gaap	Deposits Assets Current DepositsAssetsCurrent	4245	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	6055678	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	6918420	usd
CY2024Q3	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	7350364	usd
CY2023Q3	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	9131987	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1495937	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1698243	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8129753	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10188126	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	165492	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	197704	usd
CY2024Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	2319101	usd
CY2023Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	2319101	usd
CY2024Q3	us-gaap	Inventory Noncurrent InventoryNoncurrent	1475441	usd
CY2023Q3	us-gaap	Inventory Noncurrent InventoryNoncurrent	74669	usd
CY2024Q3	us-gaap	Assets Assets	26991766	usd
CY2023Q3	us-gaap	Assets Assets	30528250	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1448467	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2009786	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	566042	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5585846	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1049581	usd
CY2024Q3	cvm	Amounts Due To Employees Current AmountsDueToEmployeesCurrent	363306	usd
CY2023Q3	cvm	Amounts Due To Employees Current AmountsDueToEmployeesCurrent	557244	usd
CY2024Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2010995	usd
CY2023Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1771804	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	226969	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	197431	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1652949	usd
CY2024Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	125000	usd
CY2023Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	125000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	14124683	usd
CY2023Q3	us-gaap	Liabilities Liabilities	17313360	usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	200000	shares
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	63787104	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	637870	usd
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	474223	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	526241074	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	499832063	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-514011861	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-487091396	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	12867083	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	13214890	usd
CY2024	cvm	Property And Equipment Purchases Included In Current Liabilities PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities	32954	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	26991766	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	30528250	usd
CY2024	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18161451	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22471496	usd
CY2024	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8191023	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9004578	usd
CY2023	cvm	Property And Equipment Purchases Included In Current Liabilities PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities	51650	usd
CY2024	us-gaap	Operating Expenses OperatingExpenses	26352474	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	31476074	usd
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	-26352474	usd
CY2024	cvm	Capitalized Intangible Assets Costs Included In Current Liabilities CapitalizedIntangibleAssetsCostsIncludedInCurrentLiabilities	0	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-31476074	usd
CY2023	cvm	Capitalized Intangible Assets Costs Included In Current Liabilities CapitalizedIntangibleAssetsCostsIncludedInCurrentLiabilities	13211	usd
CY2024	cvm	Purchase Of Assets Under Finance Leases PurchaseOfAssetsUnderFinanceLeases	20797	usd
CY2023	cvm	Purchase Of Assets Under Finance Leases PurchaseOfAssetsUnderFinanceLeases	0	usd
CY2024	us-gaap	Interest Expense InterestExpense	745673	usd
CY2023	us-gaap	Interest Expense InterestExpense	675416	usd
CY2024	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	177682	usd
CY2024	cvm	Finance Lease Obligation Included In Accounts Payable FinanceLeaseObligationIncludedInAccountsPayable	1320	usd
CY2023	cvm	Finance Lease Obligation Included In Accounts Payable FinanceLeaseObligationIncludedInAccountsPayable	1451	usd
CY2024	cvm	Consulting Services Paid With Issuance Of Common Stock ConsultingServicesPaidWithIssuanceOfCommonStock	759901	usd
CY2023	cvm	Consulting Services Paid With Issuance Of Common Stock ConsultingServicesPaidWithIssuanceOfCommonStock	565980	usd
CY2024	cvm	Financing Costs Included In Current Liabilities FinancingCostsIncludedInCurrentLiabilities	38950	usd
CY2023	cvm	Financing Costs Included In Current Liabilities FinancingCostsIncludedInCurrentLiabilities	77703	usd
CY2024	cvm	Accrued Consulting Services To Be Paid Under Share Based Payment Arrangement AccruedConsultingServicesToBePaidUnderShareBasedPaymentArrangement	0	usd
CY2023	cvm	Accrued Consulting Services To Be Paid Under Share Based Payment Arrangement AccruedConsultingServicesToBePaidUnderShareBasedPaymentArrangement	55000	usd
CY2024	us-gaap	Interest Paid Net InterestPaidNet	923807	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	1062564	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-42813	usd
CY2024	us-gaap	Profit Loss ProfitLoss	-26920465	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-32194303	usd
CY2024	cvm	Modification Of Warrants ModificationOfWarrants	-659456	usd
CY2023	cvm	Modification Of Warrants ModificationOfWarrants	-171552	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-27579921	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-32365855	usd
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.51
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.73
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54044989	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44479865	shares
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	32163207	usd
CY2023	cvm	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised	447291	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	207593	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	565980	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	6122497	usd
CY2023	cvm	Incentive Stock Forfeited Amount IncentiveStockForfeitedAmount	22200	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	6308431	usd
CY2023	cvm	Cost Incurred In Issuance Of Stock CostIncurredInIssuanceOfStock	383606	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-32194303	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	13214890	usd
CY2024	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	218717	usd
CY2024	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	759901	usd
CY2024	cvm	Proceeds From The Sale Of Common Stock And Pre Funded Warrants Amount ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsAmount	23518200	usd
CY2024	cvm	Exercise Of Pre Funded Warrants Amount ExerciseOfPreFundedWarrantsAmount	56800	usd
CY2024	cvm	Purchase Of Stock By Officers And Directors Amount PurchaseOfStockByOfficersAndDirectorsAmount	80620	usd
CY2024	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	4270180	usd
CY2024	cvm	Cost Incurred In Issuance Of Stock CostIncurredInIssuanceOfStock	2331760	usd
CY2024	us-gaap	Profit Loss ProfitLoss	-26920465	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	12867083	usd
CY2024	us-gaap	Profit Loss ProfitLoss	-26920465	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-32194303	usd
CY2024	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3969183	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3958334	usd
CY2024	us-gaap	Other Noncash Expense OtherNoncashExpense	4873	usd
CY2023	us-gaap	Other Noncash Expense OtherNoncashExpense	15292	usd
CY2024	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	858498	usd
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	655740	usd
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	4270180	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	6286231	usd
CY2024	cvm	Common Stock Contributed To Employee Benefit Plan CommonStockContributedToEmployeeBenefitPlan	218717	usd
CY2023	cvm	Common Stock Contributed To Employee Benefit Plan CommonStockContributedToEmployeeBenefitPlan	207593	usd
CY2024	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-72674	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-151935	usd
CY2024	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	172608	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	156727	usd
CY2024	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-745	usd
CY2023	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	2323346	usd
CY2024	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-460576	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	257845	usd
CY2024	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-458489	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	207089	usd
CY2024	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-193938	usd
CY2023	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	85756	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18811206	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22848561	usd
CY2024	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	94875	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	361892	usd
CY2024	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	13211	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	10370	usd
CY2024	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-108086	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-372262	usd
CY2024	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	23575000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6552497	usd
CY2024	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2370513	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	744913	usd
CY2024	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	80620	usd
CY2023	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	0	usd
CY2024	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	447291	usd
CY2024	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	1773377	usd
CY2023	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	1560455	usd
CY2024	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	450000	usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	usd
CY2024	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	450000	usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	19511730	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4694420	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	592438	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-18526403	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4145735	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22672138	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4738173	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4145735	usd
CY2024	cvm	Liquidity Disclosure Textblock LiquidityDisclosureTextblock	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>2</strong><strong>.</strong> <strong>LIQUIDITY </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company has incurred significant costs since its inception for the acquisition of certain proprietary technology and scientific knowledge relating to the human immunological defense system, patent applications, research and development, administrative costs, construction and expansion of manufacturing and laboratory facilities and conducting clinical trials. The Company has funded such costs primarily with proceeds from loans and the public and private sale of its securities. The Company will be required to raise additional capital or find additional long-term financing to continue with its efforts to bring Multikine, the Company’s lead investigational therapy, to market. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to obtain approval from any regulatory agency for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">To finance the Company through marketing approval, the Company plans to raise additional capital in the form of corporate partnerships, and debt and/or equity financings. The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because Multikine showed great survival benefit in the Phase III study in one of the two treatment arms for advanced primary head and neck cancer. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all. If the Company does not raise the necessary amounts of money, it may have to curtail its operations until such time as it is able to raise the required funding. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Due to the Company’s recurring losses from operations and future liquidity needs, there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p>
CY2024Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2024	cvm	Equity Warrants Exercised EquityWarrantsExercised	5680000	shares
CY2024	cvm	Common Stock Issued For Service Shares CommonStockIssuedForServiceShares	409932	shares
CY2023	cvm	Common Stock Issued For Service Shares CommonStockIssuedForServiceShares	249997	shares
CY2024	cvm	Patents Weighted Average Amortization Period PatentsWeightedAverageAmortizationPeriod	P8Y
CY2024	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	32000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	38000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	29000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	25000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	22000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	19000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	16000	usd
CY2024Q3	cvm	Total Finite Lived Intangible Assets Amortization Expense TotalFiniteLivedIntangibleAssetsAmortizationExpense	165000	usd
CY2024Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	11645000	usd
CY2024Q3	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	347000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	168000	usd
CY2024Q3	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	0	usd
CY2023Q3	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	0	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	7.30
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.22
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	8.02
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	3.73
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.36
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	1.94
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	6857560	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.69
CY2024	cvm	Employee Contributions To Defined Contribution Plans EmployeeContributionsToDefinedContributionPlans	10000	usd
CY2024	cvm	Percentage Of Employee Contributions To Defined Contribution Plans PercentageOfEmployeeContributionsToDefinedContributionPlans	0.06	pure
CY2024	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	900000	usd
CY2023	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	1100000	usd
CY2024Q3	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	2747000	usd
CY2024Q3	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	2838000	usd
CY2024Q3	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	2929000	usd
CY2024Q3	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	3021000	usd
CY2024Q3	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	255000	usd
CY2024Q3	us-gaap	Finance Lease Liability FinanceLeaseLiability	9969000	usd
CY2024Q3	cvm	Finance Lease Liability Current Portion FinanceLeaseLiabilityCurrentPortion	2011000	usd
CY2024Q3	cvm	Finance Lease Liability Noncurrent Portion FinanceLeaseLiabilityNoncurrentPortion	7958000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	366000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	287000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	277000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	285000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	294000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2255000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1653000	usd
CY2024Q3	cvm	Operating Lease Obligationy Current OperatingLeaseObligationyCurrent	227000	usd
CY2024Q3	cvm	Operating Lease Obligationy Noncurrent OperatingLeaseObligationyNoncurrent	1426000	usd
CY2024Q2	cvm	Description Of Modification Of Warrants DescriptionOfModificationOfWarrants	the Company modified the terms of Series UU, X, Y, N, MM, NN and RR warrants by extending the expiration dates by twenty-four (24) months from their current expiration dates. The incremental cost of this extension was approximately $0.7 million, which was recorded as a deemed dividend
CY2024	cvm	Equity Warrants Exercised EquityWarrantsExercised	5680000	shares
CY2023	cvm	Proceed From Issuance Or Sale Of Equity ProceedFromIssuanceOrSaleOfEquity	400000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	217752	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3715000	shares
CY2024Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	1.00
CY2024	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	7130000	shares
CY2024Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.99
CY2024Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9700000	usd
CY2024	cvm	Net Issuance Costs NetIssuanceCosts	1100000	usd
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3875000	shares
CY2024Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	2
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	7000000	usd
CY2024Q1	cvm	Net Issuance Costs NetIssuanceCosts	700000	usd
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2490000	shares
CY2023Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	2
CY2023Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4500000	usd
CY2023Q4	cvm	Net Issuance Costs NetIssuanceCosts	500000	usd
CY2024	cvm	Warrants Used For Calculation Of Earning Per Share WarrantsUsedForCalculationOfEarningPerShare	1450000	shares
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-27579921	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-32365855	usd
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54044989	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44479865	shares
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.51
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.73
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47422304	shares
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10188126	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8129753	usd
CY2024	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2135000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2114000	usd
CY2024Q3	cvm	Deferred Tax Asset Fixed Assets Intangibles And Capitalized Rd DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd	14062000	usd
CY2024	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Concentration of Credit Risk</em> – Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents. The Company maintains its cash and cash equivalents with high quality financial institutions. At times, these accounts may exceed federally insured limits. The Company has not experienced any losses in such bank accounts. The Company believes it is not exposed to significant credit risk related to cash and cash equivalents. All non-interest bearing cash balances were fully insured up to $250,000 at September 30, 2024 and 2023. </p>
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Use of Estimates</em> – The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures. These estimates are based on management’s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, share-based compensation, useful lives for depreciation and amortization of long-lived assets, right-of-use assets and lease liabilities, deferred tax assets and the related valuation allowance. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year. Additionally, in calculating the right-of-use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms. The Company considers the estimates used in valuing the stock options and the lease assets and liabilities to be significant. </p>
CY2023	cvm	Equity Warrants Exercised EquityWarrantsExercised	217752	shares
CY2023	cvm	Proceeds From Equity Warrants Exercised ProceedsFromEquityWarrantsExercised	447291	usd
CY2024Q3	us-gaap	Fixtures And Equipment Gross FixturesAndEquipmentGross	4167828	usd
CY2023Q3	us-gaap	Fixtures And Equipment Gross FixturesAndEquipmentGross	4109070	usd
CY2024Q3	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	104593	usd
CY2023Q3	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	99296	usd
CY2024Q3	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	13924724	usd
CY2023Q3	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	13924724	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	18197145	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	18133090	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10067392	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7944964	usd
CY2024Q3	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	829716	usd
CY2023Q3	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	853445	usd
CY2024Q3	cvm	Accumulated Amortization AccumulatedAmortization	-664224	usd
CY2023Q3	cvm	Accumulated Amortization AccumulatedAmortization	-655741	usd
CY2024Q3	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	165492	usd
CY2023Q3	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	197704	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive	54000	usd
CY2024Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	34673000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	30829000	usd
CY2023Q3	cvm	Deferred Tax Asset Fixed Assets Intangibles And Capitalized Rd DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd	15196000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	11579000	usd
CY2024Q3	cvm	Lease Liabilities LeaseLiabilities	2752000	usd
CY2023Q3	cvm	Lease Liabilities LeaseLiabilities	3400000	usd
CY2024Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	932000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1221000	usd
CY2024Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Compensated Absences DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences	188000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Compensated Absences DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences	298000	usd
CY2024Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	64599000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	62691000	usd
CY2024Q3	cvm	Right Of Use Assets RightOfUseAssets	-2095000	usd
CY2023Q3	cvm	Right Of Use Assets RightOfUseAssets	-2713000	usd
CY2024Q3	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	2095000	usd
CY2023Q3	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	2713000	usd
CY2024Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	62504000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	59978000	usd
CY2024Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	62504000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	59978000	usd
CY2024Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.1197	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.0158	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.0268	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.0405	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0232	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0162	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0000	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0000	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.0939	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2185	pure
CY2024	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000	pure
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.0089	pure
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.0166	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.9918	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.0018	pure
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0377	pure
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0458	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0341	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0425	pure
CY2024	cvm	Expected Life Of Options Min1 ExpectedLifeOfOptionsMin1	P9Y7M9D
CY2023	cvm	Expected Life Of Options Max ExpectedLifeOfOptionsMax	P9Y7M20D
CY2023	cvm	Expected Life Of Options Min1 ExpectedLifeOfOptionsMin1	P9Y7M17D
CY2024	cvm	Expected Life Of Options Max ExpectedLifeOfOptionsMax	P9Y7M28D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	5896397	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	3.63
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	952256	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	2065500	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	213165	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	6796476	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	2.25
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	1501583	shares
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	1969000	shares
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	406333	shares
CY2024	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	136868	shares
CY2024	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	219000	usd
CY2023	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	97004	shares
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	208000	usd
CY2024Q3	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	11790000	usd
CY2024Q3	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	1821000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	746000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	602000	usd
CY2024	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17497800	shares
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15997278	shares

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001654954-25-000288-index-headers.html	Edgar Link	pending
0001654954-25-000288-index.html	Edgar Link	pending
0001654954-25-000288.txt	Edgar Link	pending
0001654954-25-000288-xbrl.zip	Edgar Link	pending
cvm-20240930.xsd	Edgar Link	pending
cvm_10k.htm	Edgar Link	pending
cvm_10kimg10.jpg	Edgar Link	pending
cvm_10kimg11.jpg	Edgar Link	pending
cvm-20240930_pre.xml	Edgar Link	unprocessable
cvm-20240930_lab.xml	Edgar Link	unprocessable
cvm_10kimg12.jpg	Edgar Link	pending
cvm_10kimg13.jpg	Edgar Link	pending
cvm_10kimg14.jpg	Edgar Link	pending
cvm_10kimg15.jpg	Edgar Link	pending
cvm_10kimg16.jpg	Edgar Link	pending
cvm_10kimg17.jpg	Edgar Link	pending
cvm_10kimg18.jpg	Edgar Link	pending
cvm_ex19.htm	Edgar Link	pending
cvm_ex231.htm	Edgar Link	pending
cvm_ex31.htm	Edgar Link	pending
cvm_ex32.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
cvm_10k_htm.xml	Edgar Link	completed
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
cvm-20240930_cal.xml	Edgar Link	unprocessable
cvm-20240930_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CVM
CEL SCI CORP Stock $cvm

2025 Q1 Form 10-K Financial Statement

#000165495425000288 Filed on January 13, 2025

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CVM CEL SCI CORP Stock $cvm

2025 Q1 Form 10-K Financial Statement

#000165495425000288 Filed on January 13, 2025

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CVM
CEL SCI CORP Stock $cvm